Concepedia

Anna Dahlman

AD

Statistics

Publications

14

Citations

665

H-Index

12

Active since

1992

Affiliations

Lund University(Current)

Symphogen (Denmark)

Malmö University

Skåne University Hospital

Memorial Sloan Kettering Cancer Center

Anna Dahlman is an author at Lund University specializing in oncology, medicine, and molecular oncology.

ORCID

Publications per year

1992–2022

14

Publications

14

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand et al. · Journal for ImmunoTherapy of Cancer · 2019 · 114 citations · Full text

, , +17

Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells

Rebecka Hellsten, Martin Johansson, Anna Dahlman et al. · PLoS ONE · 2011 · 90 citations · Full text

, , +15

Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity

Helle J. Jacobsen, Thomas T. Poulsen, Anna Dahlman et al. · Clinical Cancer Research · 2015 · 84 citations

, , +16

Galiellalactone is a novel therapeutic candidate against hormone‐refractory prostate cancer expressing activated Stat3

Rebecka Hellsten, Martin Johansson, Anna Dahlman et al. · The Prostate · 2007 · 84 citations · Full text

, , +13

Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance

Mikkel W. Pedersen, Helle J. Jacobsen, Klaus Koefoed et al. · Molecular Cancer Therapeutics · 2015 · 53 citations

, , +17

1–5 of 14